V LeMaitre® Your Peripheral Vision® Disclaimers Forward-Looking Statements This presentation contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" in our Annual ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 63 Second Avenue, Burlington, Massachus ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q2 2020 Earnings Conference Call July 23, 2020 5:00 PM ET Company Participants Joseph Pellegrino - Chief Financial Officer, Treasurer and Secretary George LeMaitre - Chairman and Chief Executive Officer David Roberts - President Conference Call Participants Cecilia Furlong - Canaccord Genuity Group Inc. Andrew Ranieri - Stifel, Nicolaus & Co., Inc. Brooks O'Neil - Lake Street Capital Markets, LLC Michael Petusky - Barrington Research Associates, Inc. James Sidoti - Sido ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Or Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 (Exact name of registrant as specified in its charter) Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the pr ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q1 2020 Results Conference Call April 30, 2020 5:00 PM ET Company Participants JJ Pellegrino - Chief Financial Officer George LeMaitre - Chairman & CEO David Roberts - President Conference Call Participants Jim Sidoti - Sidoti and Company Cecilia Furlong - Canaccord Genuity Frank Takkinen - Lake Street Capital Markets Mike Petusky - Barrington Research Operator Welcome to the LeMaitre Vascular Q1 2020 financial results conference call. As a reminder, today's call is bei ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Financial Data and Key Metrics Changes - In Q4 2019, the company reported record sales of $30.2 million, an increase of 6% year-over-year [7] - Adjusted operating income for Q4 2019 was $4.9 million, down 12% from Q4 2018, primarily due to lower gross margins and increased operating expenses [15] - The gross margin for Q4 2019 was 66%, a decline of 1.7% compared to the prior year [14] - For the full year 2019, organic growth improved to 6%, with adjusted operating income growth of 3% [10][11] Business Line Data and Key Metrics Changes - Biologics accounted for 30% of sales in Q4 2019, with significant contributions from biologic patches and the recently acquired CardioCel patches generating $1.4 million in sales [9][7] - The Tru-Incise acquisition contributed $500,000 in sales during Q4 2019 [7] Market Data and Key Metrics Changes - The Americas experienced a record quarter with a 6% growth, Europe grew by 4%, and Asia-Pacific saw a significant increase of 20%, driven by a 53% growth in exports [8] - Direct sales in Asia-Pacific markets of China, Japan, and Australia all grew by 10% [8] Company Strategy and Development Direction - The company plans to leverage its expertise in biologics through the CardioCel acquisition and is launching cardiac allografts in the U.S. and Canada [9] - The company aims for 10% sales growth and 17% operating income growth in 2020, indicating a focus on expanding its product offerings and market reach [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the transition from MDD to MDR in Europe, which requires more costly testing and data collection [19] - The company expects to resolve these regulatory challenges in H1 2020 and has taken steps to mitigate potential sales impacts by overstocking inventory [20] - Management expressed confidence in achieving record revenue growth in 2020, driven by acquisitions and organic growth [16] Other Important Information - The Board increased the dividend payout by 12%, marking the ninth consecutive year of dividend increases [12] - The company ended Q4 2019 with $32.7 million in cash, a decrease attributed to acquisition-related payments and capital expenditures [17] Q&A Session Summary Question: Can you walk through the quarterly growth and operating margin leverage for 2020? - Management indicated that sales growth would be fairly even throughout the year, with expectations for gross margin improvements in Q2 due to manufacturing efficiencies [23][24] Question: What are your thoughts on the medium to long-term trajectory of gross margin? - Management acknowledged that gross margin is important and that recent acquisitions have impacted margins, but they expect to improve margins over time as integration progresses [26] Question: Can you clarify the restrained 2020 OpEx spending? - Management clarified that OpEx is expected to grow by 6% in 2020, down from 10% in 2019, and emphasized that cost-cutting initiatives would not significantly hinder growth [30][31] Question: What is the expected organic growth for 2020? - Management confirmed expectations of 10% reported growth and 5% organic growth, with some headwinds from the OEM business and regulatory changes [32] Question: What was the pricing trend in Q4? - Pricing was down approximately 3% in Q4, driven by a large disposables order in China, while unit sales were up 4.5% [36] Question: Can you provide a breakdown of the rep count at the end of the year? - The company reported 54 reps in the Americas, 40 in Europe, and 18 in Asia-Pacific, totaling 112 worldwide [43] Question: What is the expected contribution from the Admedus acquisition? - Management projected around $7 million in revenue from the CardioCel and VascuCel products for 2020 [50] Question: How much is being spent on MDD to MDR transition? - Management estimated an incremental cost of about $1 million for the transition in 2020 [78]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (St ...